Daniel Arber to Myeloproliferative Disorders
This is a "connection" page, showing publications Daniel Arber has written about Myeloproliferative Disorders.
Connection Strength
6.086
-
Guide to the Diagnosis of Myeloid Neoplasms: A Bone Marrow Pathology Group Approach. Am J Clin Pathol. 2023 10 03; 160(4):365-393.
Score: 0.818
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228.
Score: 0.761
-
Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. Am J Hematol. 2022 05; 97(5):514-518.
Score: 0.732
-
Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant? Best Pract Res Clin Haematol. 2020 06; 33(2):101139.
Score: 0.630
-
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 05 19; 127(20):2391-405.
Score: 0.487
-
STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica. 2014 Jul; 99(7):e105-7.
Score: 0.427
-
Pathology of the myeloproliferative diseases. Hematol Oncol Clin North Am. 2003 Oct; 17(5):1101-27.
Score: 0.204
-
The international consensus classification of eosinophilic disorders and systemic mastocytosis. Am J Hematol. 2023 08; 98(8):1286-1306.
Score: 0.200
-
Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation. Leuk Res. 2023 04; 127:107033.
Score: 0.196
-
Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study. Mod Pathol. 2023 03; 36(3):100016.
Score: 0.194
-
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022 11 24; 140(21):2228-2247.
Score: 0.193
-
International Consensus Classification for myeloid neoplasms at-a-glance. Am J Hematol. 2023 01; 98(1):6-10.
Score: 0.192
-
The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol. 2023 01; 98(1):166-179.
Score: 0.191
-
EAHP 2020 workshop proceedings, pediatric myeloid neoplasms. Virchows Arch. 2022 Oct; 481(4):621-646.
Score: 0.188
-
Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. Blood Adv. 2021 09 14; 5(17):3492-3496.
Score: 0.177
-
Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol. 2018 05; 31(5):690-704.
Score: 0.138
-
A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. Cancer Genet. 2017 Oct; 216-217:10-15.
Score: 0.131
-
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Myeloproliferative Neoplasms. Arch Pathol Lab Med. 2016 Jul; 140(7):675-7.
Score: 0.119
-
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30; 114(5):937-51.
Score: 0.075
-
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017 08; 102(8):1352-1360.
Score: 0.033